Abcam opens new APAC hub in Singapore

PRESS RELEASE

Abcam opens new APAC hub in Singapore

Its new home in the Lion City will support the Asia Pacific (APAC) region, which accounts for 30% of all global pharmaceutical spending¹

Cambridge, UK – April 27, 2022 – Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator working together with life scientists to advance research and enable faster breakthroughs, officially opens its newest regional hub in Singapore today.

With healthcare expenditure in Asia projected to grow by 135% to USD 2.3 trillion come 2026², the life sciences sector in the region continues to expand rapidly. Abcam’s new site will service the growing APAC life sciences community, offering scientific and technical support and providing a commercial headquarters for the region.

For the past two decades, we have witnessed how the quality of science, investment in R&D, and growing presence of world-class talent have made APAC a central place to drive innovation and advances in life science and healthcare. We’re excited to be at the heart of the dynamic life sciences ecosystem in Singapore. The new regional hub will strengthen our interactions with researchers in APAC and will help the global life sciences community push the boundaries of research.

Alan Hirzel CEO at Abcam

At its new base at the Biopolis Biomedical Research Hub — just a stone’s throw from some of the region’s leading research centers—Abcam joins over 350 life sciences companies, including eight of the top 10 global pharma players, that have laid down roots in the country¹.

“We are pleased that Abcam has chosen Singapore as the location of its new APAC hub. We are confident that by tapping into our vibrant healthcare and innovation ecosystems, Abcam will be able to support the life sciences community in Singapore to meet the region’s growing healthcare needs.“

Ms Junie Fo
Vice President, Investment Facilitation, Singapore Economic Development Board

The official opening ceremony was graced by Guest-of-Honor Professor Tan Sze Wee, Assistant Chief Executive of Enterprise at Singapore’s Agency for Science, Technology and Research (A*STAR), alongside members of Abcam’s Executive Leadership team. This move marks a major milestone in Abcam’s growth, building on its recent expansion in Shanghai and Hangzhou (which continues to serve customers in mainland China) and Adelaide, Australia.

—ENDS—